

Published in final edited form as:

*Hypertension*. 2017 June ; 69(6): 1207–1216. doi:10.1161/HYPERTENSIONAHA.117.09156.

## Physiological and Pathological Roles in Human Adrenal of the Glomeruli-Defining Matrix Protein Nephronectin (NPNT)

Ada Ee Der Teo<sup>1</sup>, Sumedha Garg<sup>1</sup>, Timothy Isaac Johnson<sup>2</sup>, Wanfeng Zhao<sup>3</sup>, Junhua Zhou<sup>1,4</sup>, Celso Enrique Gomez-Sanchez<sup>5</sup>, Mark Gurnell<sup>6</sup>, and Morris Jonathan Brown<sup>1,4,\*</sup>

<sup>1</sup>Clinical Pharmacology Unit, Centre for Clinical Investigation, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK

<sup>2</sup>MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK

<sup>3</sup>Tissue Bank, Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK

<sup>4</sup>Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary University of London, London, UK

<sup>5</sup>Division of Endocrinology, Department of Medicine, The University of Mississippi Medical Centre, Jackson, MS, USA; Research and Medicine Services, G.V. (Sonny) Montgomery VA Medical Centre, Jackson, MS, USA

<sup>6</sup>Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge & NIHR Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK

### Abstract

Primary aldosteronism is a common cause of hypertension, which becomes refractory if undiagnosed, but potentially curable when due to an aldosterone-producing adenoma (APA). The discovery of somatic mutations and differences in clinical presentations led to recognition of small but common zona glomerulosa (ZG)-like adenomas, distinct from classical large zona fasciculata (ZF)-like adenomas. The inverse correlation between APA size and aldosterone synthase expression prompted us to undertake a systematic study of genotype-phenotype relationships.

Following a microarray comparing tumor subtypes, in which *nephronectin* (*NPNT*) was the most highly (>12-fold) upregulated gene in ZG-like APAs, we aimed to determine its role in physiological and pathological aldosterone production.

NPNT was identified by immunohistochemistry as a secreted matrix protein expressed exclusively around aldosterone-producing glomeruli in normal adrenal ZG, and in aldosterone-dense ZG-like APAs; the highest expression was in ZG-like APAs with gain-of-function *CTNNB1* mutations, whose removal cured hypertension in our patients. NPNT was absent from normal ZF, ZF-like APAs, and ZG adjacent to an APA. Its production was regulated by canonical Wnt and NPNT

\* Correspondence to Prof Morris Jonathan Brown, Centre for Clinical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary University of London, London, EC1M 6BQ, United Kingdom. Tel: 020 7882 3901, morris.brown@qmul.ac.uk.

#### Conflict of Interest/Disclosure

None.

transfection or silencing increased or reduced aldosterone production respectively. NPNT was pro-adhesive in primary adrenal and APA cells, but anti-adhesive and anti-apoptotic in immortalized adrenocortical cells.

The discovery of *NPNT* in the adrenal helped recognition of a common subtype of APAs, and a pathway by which Wnt regulates aldosterone production. We propose that this arises through NPNT's binding to cell-surface integrins, stimulating cell-cell contact within glomeruli which define ZG. Therefore, NPNT or its cognate integrin could present a novel therapeutic target.

## Keywords

hypertension; aldosterone; adenoma; extracellular matrix protein; Wnt pathway

## Introduction

5-13% of all hypertension and 20% of resistant hypertension can be attributed to primary aldosteronism, of which unilateral aldosterone-producing adenoma (APA) is the most common curable cause<sup>1,2</sup>. Early detection of APA is important due to significant increases in cardiovascular morbidity and mortality: congestive cardiac failure and ischemic heart disease are 2–5 times more prevalent<sup>3</sup>, with an increase in 14-year mortality in these patients over matched patients with essential hypertension<sup>4</sup>. Whether this additional risk is due directly to aldosterone excess, independent of high blood pressure, or reflects greater average duration of hypertension prior to diagnosis, clinical outcome is considered to benefit from prompt recognition and removal of APAs<sup>5</sup>.

Over the past decade, new molecular stratifications have enabled the recognition of a group of smaller zona glomerulosa (ZG)-like APAs<sup>6–8</sup>. Compared to the classical large lipid-laden zona fasciculata (ZF)-like APA with mutations in inward rectifier potassium channel 4 (*KCNJ5*)<sup>6</sup>, not only is this ZG-like subtype of APA histologically and biochemically different, it also harbors hallmark somatic mutations in genes encoding a subunit of the voltage-gated calcium channel (*CACNA1D*)<sup>8</sup>, Na<sup>+</sup>/K<sup>+</sup>-ATPase (*ATP1A1*)<sup>8,9</sup>, Ca<sup>2+</sup>-ATPase (*ATP2B3*)<sup>9</sup>, or the Wnt pathway mediator  $\beta$ -catenin (*CTNNB1*)<sup>10</sup>. Biochemically, these smaller ZG-like APAs have a higher capacity for aldosterone production; semiquantitative analysis of immunohistochemical staining has revealed that CYP11B2 score is inversely correlated with tumor size and volume<sup>11,12</sup>. In addition, ZG-like APAs are more responsive to angiotensin II (All), with higher levels of type 1 AII receptor mRNA<sup>13,14</sup>. However, due to their small size, they are readily overlooked on cross-sectional imaging, as CT is unable to reliably detect adrenal tumors smaller than 5-6mm<sup>15</sup>. We hypothesized that specific gene products are responsible for the increased hormone production in these aldosterone-dense APAs and can potentially be used as a diagnostic biomarker when imaging proves inconclusive.

In seeking transcriptomic evidence to identify possible pathways of aldosterone production specific to the more compact, aldosterone-synthase dense APAs, we compared *CACNA1D*/*ATP1A1*-mutant with *KCNJ5*-mutant APAs<sup>8</sup>. Extracellular matrix (ECM) gene *nephronectin* (*NPNT*) was found to be the most upregulated, by 12-fold, in the former, and

confirmed a categorical difference between APA genotypes by immunohistochemistry. Discovered in the kidney in 2001<sup>16</sup>, *NPNT* was recently found to be a downstream Wnt target in the epidermis<sup>17</sup>. This may be relevant in the adrenal, where normal adrenocortical development and steroidogenic activity of the ZG, are dependent on the canonical Wnt pathway<sup>18</sup>.

Further examination of *NPNT*'s distribution presented in this paper led us to hypothesize a key role in bringing ZG cells together to form functional units for aldosterone production through intercellular communication. This is supported by the observation, in rat ZG cells, of numerous tight junctions likely to be important in the establishment of electrical coupling<sup>19</sup>, and the more recent discovery, only in intact adrenal slices, of oscillating membrane potentials regulating aldosterone secretion<sup>20</sup>.

In this study, we have found that *NPNT* is directly involved in the physiological secretion of aldosterone in the adrenal. By using both cell-lines and primary human adrenal cells, we have also uncovered a previously unknown role of *NPNT* in adhesion and cell survival.

## Methods

### Human subjects

Human adrenal tissues from patients who underwent adrenalectomy after being diagnosed with unilateral APA or pheochromocytoma were obtained from Cambridge University Hospitals' Human Research Tissue Bank post-surgery at Addenbrooke's Hospital, Cambridge, United Kingdom. All tissues were obtained with approval from the Cambridgeshire Research Ethics Committee with written informed consent prior to surgery. Further details are provided in the Data Supplement and clinical features in Table S1.

### Cell culture

Human adrenocortical carcinoma H295R cells were obtained from the American Type Culture Collection (ATCC CRL-2128), and grown in DMEM/Nutrient F-12 Ham supplemented with 10% FBS, 100 U penicillin, 0.1 mg/ml streptomycin, 0.4 mM L-glutamine and ITS at 37 °C in 5% CO<sub>2</sub>. HEK cells were obtained from the American Type Culture Collection (ATCC CRL-1573), and grown in DMEM supplemented with 10% FBS.

### Gene overexpression and silencing

Gene overexpression was carried out using lipid-mediated cell transfection Lipofectamine 3000 (Thermo Fisher), while gene silencing was achieved using DharmaFECT 1 lipid transfection reagent (Dharmacon), both according to manufacturer's instructions. Cells were harvested for analysis of mRNA and protein expression after 48h. Further details are provided in the Data Supplement.

### RNA extraction, reverse transcription and quantitative real-time polymerase chain reaction (qRT-PCR)

50-100mg of tissue or  $1 \times 10^5$  cells were used for each RNA extraction. Further details are provided in the Data Supplement. qRT-PCR was performed using TaqMan ABI probes

(Applied Biosystems) for *NPNT* (Hs01568126), *ITGB1* (Hs00559595) and *BCL2* (Hs00608023). *CYP11B2* expression was quantified using custom-made TaqMan probes (Invitrogen) previously validated for specificity<sup>21</sup>.

### Immunohistochemistry

Immunohistochemistry was carried out using the peroxidase-antiperoxidase method on fresh frozen human tissue. In cases where fresh frozen tissue was unavailable, immunohistochemistry was performed on formalin-fixed, paraffin-embedded adrenal sections (4  $\mu$ m) using an automated immunostainer with cover tile technology (Bond-III system, Leica Biosystems). NPNT antibody (HPA003711, Sigma; 1:50 dilution), and CYP11B2 antibody (custom mouse anti-human antibody from Dr Celso E. Gomez-Sanchez)<sup>22</sup> were used as the primary antibodies. Further details are provided in the Data Supplement.

### Aldosterone measurement

Supernatant from cultured cells was used for aldosterone quantification using the Homogenous Time Resolved Fluorescence (HTRF) assay (Cisbio assays) based on the Fluorescence Resonance Energy Transfer (FRET) technology, according to manufacturer's instructions. The final fluorescence readout was conducted using a Pherastar FS microplate reader (BMG Labtech). Aldosterone concentrations were then normalized to total cell protein, quantified by the bicinchoninic acid (BCA) protein assay (Pierce Biotechnology).

### Firefly/ renilla luciferase assay

To measure the activity of Wnt transcriptional complex TCF/LEF, firefly and renilla luciferase activity was measured 48h after co-transfection with the Dual-Glo Luciferase Assay System (Promega) and normalized to the empty pCMV6 vector as described in the manufacturer's protocol. Canonical Wnt signaling was quantified using the Cignal TCF/LEF Reporter (luc) Kit (SABiosciences).

### Cell confluency and cytotoxicity assay

To measure changes in H295R cell confluency post-*NPNT* silencing, time-lapsed images were obtained using an Incucyte system (Essen BioScience). To differentiate changes in cell proliferation from cytotoxicity, cell-impermeant cyanine dimer nucleic acid stain YOYO-1 (Y3601, Life Technologies) was utilized. Further details are provided in the Data Supplement.

### Annexin V-propidium iodide dual stain

To assess apoptosis over time, cells were double-labelled with Annexin V-APC (550474, BD Pharmingen) and propidium iodide (PI) (Sigma). After silencing, adherent cells were trypsinized, added to any detached cells in the supernatant as previously described<sup>23</sup>, stained with Annexin V-PI, and analyzed with the FACSCanto II flow cytometer (Becton-Dickinson). Further details are provided in the Data Supplement.

### Xcelligence cell impedance measurement and Hoechst stain assay

To evaluate changes in adhesion in response to NPNT, wells of an E-Plate 16 (ACEA Biosciences) were pre-coated with PBS, or 10 $\mu$ g/ml of BSA, NPNT or laminin for 1 h at 37°C as previously described<sup>24</sup>. Cell adhesion was also measured by Hoechst dye quantification of cells remaining on pre-coated wells post-wash. Further details are provided in the Data Supplement.

### Proteins and chemicals

Proteins used in this study were BSA (A9576, Sigma), NPNT (4298-NP-050, R&D systems), Fibronectin (FC010, Millipore) and laminin (AG56P, Millipore). The selective porcupine inhibitor, LGK-974 (1  $\mu$ M; Selleck Chemicals), as used previously<sup>25</sup>, was used to analyze the effect of blocking all Wnt secretion.

### Statistical analysis

Results are expressed as mean values with standard error of the mean (SEM) and compared using the two-sided Student's t-test or by one-way ANOVA followed by Tukey's *post hoc* test. Significance level of  $P < 0.05$  was considered to indicate statistical significance. Statistical analysis was performed using Graphpad Prism (Graphpad Software Inc.)

## Results

### **NPNT is selectively expressed in the subtype of smaller ZG-like APAs and able to distinguish between the two APA classes**

Microarray analysis revealed *NPNT* to be 12.2-fold upregulated in the smaller ZG-like APAs with higher aldosterone synthetic capacity (Figure 1A). Validation with qRT-PCR revealed a nine-fold difference; both ZG-like APAs and adrenocortical carcinomas (ACCs) had significantly elevated levels of *NPNT* compared to the ZF-like APAs (Figure 1B). The two APAs with the highest levels of *NPNT* harbored gain-of-function mutations in the Wnt gene *CTNNB1*.

In a further microarray comparing the ZG and ZF of 20 human adrenals isolated via laser capture microdissection<sup>26</sup>, *NPNT* was on average two-fold more highly-expressed in the outer, aldosterone-producing zone of the ZG (Figure 1C). This selective expression was evident in protein immunohistochemistry, in which NPNT staining is localized exclusively to the ZG (Figure 1D, Figure S1). When mounted on the same slide, NPNT also makes it easy to differentiate between the two APA subtypes as there is negligible staining in ZF-like APAs (Figure 1E, Figure S2). In all cases, NPNT expression appeared extracellular and strikingly peri-glomerular, surrounding clusters of cells.

### **NPNT expression corresponds to aldosterone synthase *CYP11B2* expression**

Although the ZG is the zone of physiological aldosterone production, *CYP11B2* staining is patchy<sup>22</sup>. The overall analysis of 20 normal adrenal and APA samples revealed a significant positive correlation between *NPNT* and *CYP11B2* encoding aldosterone synthase ( $r = 0.82$ ,  $p < 0.0001$ ) (Figure 2A). At the protein level, areas of *CYP11B2* expression also corresponded consistently with NPNT staining (Figure 2B, Figure S3). We also compared

the ZG expression of genes in adrenal adjacent to a pheochromocytoma versus that next to an APA (i.e. in a state of aldosterone excess). *NPNT* was 3.6-fold upregulated in ZG, compared to ZF, when adjacent to a pheochromocytoma, but diminished or absent when adjacent to an APA (Figure 2C). The same observations were made at the protein level (Figure 2D). Similarly, *CYP11B2* was two-fold upregulated in ZG next to a pheochromocytoma vs next to an APA, and 7.8-fold higher on qRT-PCR validation.

### ***NPNT* drives aldosterone production**

*NPNT* overexpression in H295R cells increased aldosterone synthesis compared to control (Figure 3A). Similarly, silencing *NPNT* by over 75% reduced hormone production (Figure 3B). *NPNT* has been previously found to bind strongly and specifically to integrin receptor  $\alpha 8\beta 116$ , with approximately 100-fold higher affinity compared to other RGD motif-containing proteins such as fibronectin or vitronectin<sup>27</sup>. In our study, silencing of *ITGB1*, encoding integrin subunit  $\beta 1$ , by approximately 80%, caused a similar reduction in aldosterone production comparable to silencing of *NPNT* (Figure 3C). This receptor silencing was accompanied by a 3.8-fold increase in *NPNT* mRNA expression ( $p=0.01$ ).

### ***NPNT* is a Wnt target gene and produces aldosterone via this pathway**

*NPNT* was found to be a Wnt/ $\beta$ -catenin target gene in skin, being induced by Wnt activation in the bulge and hair germ cells<sup>17</sup>. We investigated the influence of Wnt on *NPNT* mRNA expression in H295R cells, using plasmids modulating Wnt signaling. To activate the Wnt canonical pathway, N47  $\beta$ -catenin, a strong constitutive inducer encoding an N-terminally truncated form of  $\beta$ -catenin resistant to proteolysis<sup>28</sup>, was expressed. This led to a near-doubling of *NPNT* expression levels. Conversely, to inhibit  $\beta$ -catenin-dependent gene transcription, we expressed N TCF4, a Wnt constitutive repressor due to an N-terminally truncated, dominant-negative TCF4 protein lacking the  $\beta$ -catenin interaction domain<sup>29</sup>. Wnt repression caused *NPNT* mRNA levels to halve (Figure 4A). To investigate the potential for negative feedback of *NPNT* on its own release, TCF-LEF activity was measured following changes in *NPNT* expression. Overexpressing *NPNT* caused a reduction in Wnt transcriptional activity, while silencing *NPNT* had the opposite effect (Figure 4B).

In cases where *NPNT* protein was added to the cell medium, upon addition of Wnt inhibitor LGK-974, which blocks Wnt pathways upstream by binding the Wnt chaperone, porcupine, aldosterone production was nearly diminished by half compared to controls (Figure 4C).

### ***NPNT* is pro-adhesive in normal adrenal and APA cells**

*NPNT* promotes cell adhesion in kidney mesangial cells<sup>30</sup> and cardiomyocytes<sup>31</sup>. Cell impedance was recorded as a measure of cell adhesion in wells coated with phosphate-buffered saline (PBS), negative control bovine serum albumin (BSA), *NPNT* or positive control laminin. *NPNT* was pro-adhesive in human embryonic kidney (HEK) cells, normal primary adrenal cells and cells cultured from ZF-like and ZG-like APAs (Figure 5Ai-iv). These findings are consistent with the hypothesized physiological role of *NPNT* in adrenal cell-clustering for aldosterone production.

Intriguingly, NPNT had the opposite effect on H295R cells, with cell index reaching less than 50% of that in BSA-coated wells even after 4h (Figure 5Av). This suggested that NPNT was anti-adhesive towards H295R cells, with cells tending to repel from the well surface. To re-affirm this finding, Hoechst stain assays were carried out independently, with increasing concentrations of matrix coating on wells. Post-wash, there was a concentration-dependent increase in number of cells remaining (as measured by fluorescence) in positive control laminin-coated wells. However, in NPNT-coated wells, the number of remaining cells showed no significant difference from that in BSA-coated wells at every protein concentration, indicating only background levels of adhesion (Figure 5B).

### NPNT protects H295R cells from apoptosis

Cell confluency was 41% in the non-targeting controls compared to 26% in the *NPNT*-silenced samples at 48h, as observed using kinetic live-cell imaging (Figure 6A). Kinetic measurement of cytotoxicity via the YOYO1-iodide reagent revealed over three-fold increase in fluorescent (dead) cells when *NPNT* was silenced (Figure 6B). Following this, annexin V-propidium iodide dual assay was used to monitor H295R cell staining over time. *NPNT*-silenced cells exhibited greater apoptosis over time, whereas samples with non-targeting siRNA consistently showed basal levels of apoptosis (Figure 6C).

A pro-survival factor in the intrinsic apoptotic pathway<sup>32</sup>, transcription of *B-cell lymphoma 2 (BCL2)* was greatly suppressed (>56%) in *NPNT*-silenced (si*NPNT*) cells (Figure 6D).

## Discussion

The zona glomerulosa of human adrenal is unusual among endocrine organs in that few cells produce its signature hormone, aldosterone; and yet there is a high incidence of APA occurrence which is a common curable cause of hypertension. The ZG has likely evolved primarily to protect mammals from the scarcity of salt that has been the prevailing natural state, including for most of human history. It clearly also has the ability to adapt to chronic salt excess, to which the sparsity of aldosterone synthase is usually attributed<sup>25</sup>, but perhaps imperfectly, and hence the frequent somatic mutations permitted by high rates of ZG cell migration and renewal. Our discovery of *NPNT*, and its putative roles, in the adrenal may help to explain the link between physiology and pathology.

We first discovered *NPNT* in the adrenal as the most upregulated gene in the smaller ZG-like APAs with higher aldosterone synthetic capacity, harboring mutations of *CACNA1D* or *ATP1A1*, when compared to those with a ZF-like phenotype and mutations of *KCNJ5*. We also noted the exquisite ZG selectivity of its distribution in normal adrenal cortex<sup>8</sup>. These original findings have been reproduced by Akerstrom *et al*<sup>33</sup>. Interest in finding a mechanistic link between *NPNT* expression and blood pressure control has also been raised by a large-scale genome-wide association study in which a common single-nucleotide polymorphism in *NPNT* was associated with blood pressure regulation<sup>34</sup>.

The investigations which we now report show that *NPNT* is not just a marker of ZG cells, but plays an essential role in normal adrenal physiology as a peri-glomerular ECM protein. Coupled with its steroidogenic and pro-adhesive properties, this is consistent with a

physiological role in adrenal cell-clustering to form functional aldosterone-producing units in the ZG. Our work provides evidence that a matrix protein can play a role in driving hormone synthesis, and together with the regulation of ZG cell behavior, helps us understand why the ZG may be structured as it is, and why tumors which resemble ZG are able to have a higher density of aldosterone production.

The ZG-selective staining suggests that the ECM of which NPNT is a major constituent supports zone-specific cellular behavior. In 2012, Hu *et al* made the crucial observation that isolated mouse ZG cells are too hyperpolarized to permit calcium entry; however, ZG cells in an intact adrenal slice generate spontaneous membrane oscillations sufficient for recurrent  $\text{Ca}^{2+}$  signals, whose periodicity could sustain aldosterone production<sup>20</sup>. Therefore, these findings suggest that the aldosterone-producing ability of adrenal cells requires them to co-exist in whole glomeruli, and this process could be regulated by NPNT.

Although the ZG is the zone of physiological aldosterone production, this is not carried out by all cells in the area, as evidenced by previous reports of patchy *CYP11B2* staining<sup>22</sup>. But the mechanism underlying why some ZG cells express *CYP11B2*, whilst others do not, is yet to be determined. Together with the consistent correlation between NPNT and *CYP11B2* staining, as well as evidence showing *NPNT* increases aldosterone production, we propose that the role of this matrix protein is to cluster ZG cells together to form a functional unit as indicated by its peri-glomerular staining. This is supported by the recent proposal that  $\text{Ca}^{2+}$  and  $\text{Ca}^{2+}$ -activated  $\text{K}^{+}$  channels in ZG cells, when grouped in “rosette” structures, act as a pacemaker generating the oscillations which regulate aldosterone production<sup>35</sup>. Upon *NPNT* silencing, although the cell-corrected fall in aldosterone appears relatively small (Figure 3B), the absolute change consequent on reduction in both secretion and cell number is more substantial, and likely to have considerable impact in intact ZG.

In addition, our own finding of NPNT as an exquisitely-selective ZG protein, 3.6-fold upregulated in ZG compared to ZF when adjacent to a pheochromocytoma, but diminished or absent when adjacent to an APA, suggests the disappearance of *NPNT* when physiological aldosterone secretion is not required. Analogous negative feedback has been reported in ZG adjacent to APA, where both subtypes of  $3\beta$ -hydroxysteroid dehydrogenase-isomerase ( $3\beta$ -HSD), responsible for synthesizing progesterone from pregnenolone, were found to be suppressed<sup>36</sup>.

Our results also showed that NPNT promotes adhesion in normal adrenal cells, and in both subtypes of APAs. This is consistent with previous reports of NPNT expression in hepatitis, inducing the development of granuloma-like cell clusters of hepatocytes<sup>37</sup>. Cardiomyocytes grown on NPNT not only exhibited increased adhesion, but also expressed high amounts of connexin-43 along their intercellular junctions, indicating well-established intercellular communication, and couple electrically with each other resulting in synchronous beating<sup>31</sup>.

The link between increased cell adhesion and aldosterone production lies within the Wnt signaling system. Intracellular Wnt signaling diversifies into several major pathways, including: (1) the  $\beta$ -catenin/TCF-LEF pathway (canonical Wnt), which activates nuclear target genes; (2) the planar cell polarity (PCP) pathway; and (3) the Wnt/ $\text{Ca}^{2+}$  pathway, with

the last two being classified as the non-canonical Wnt pathways<sup>38</sup>. While *NPNT* expression is itself under control of the canonical pathway, the non-canonical Wnt/PCP pathway is likely to be involved in mediating *NPNT*'s control of cell-cell adhesion and the localized assembly of ECM (Figure 4C)<sup>39</sup>. It has been shown that an aberrant PCP pathway leads to disruption of integrin  $\beta$ 1-mediated interactions and in turn, disorganization of the ECM<sup>40</sup>. In addition, in line with the proposed role of *NPNT*, integrin  $\beta$ 1 expression was reported to be crucial for adhesion of endothelial cells, with its absence causing focal adhesions to become short and disorganized<sup>41</sup>.

Although our experiments concentrated on the physiological roles of *NPNT* in normal adrenal and benign APAs, its anti-adhesive and anti-apoptotic effect on H295R cells have drawn our attention to a potential role in malignancy. ACCs, although rare, are much more devastating than APAs. *NPNT* has been shown to confer apoptosis resistance in H295R cells by modulating the expression of pro-survival protein *BCL2*, whose role is to block caspase activation<sup>32</sup>. This detachment of cells from the ECM often results in apoptotic cell death known as anoikis<sup>42</sup>. Excess secretion of ECM components suppresses the physiological induction of anoikis in maintaining normal tissue architecture<sup>43</sup>, and could explain the high levels of *NPNT* expression in adrenocortical carcinoma and immortalized H295R cells (Figure 1B).

However, benign APAs are much commoner than ACCs, and the main translational potential of *NPNT* may lie in its use as a diagnostic marker in patients with sub-centimeter APAs, whose CT scan and/or adrenal vein sampling results are inconclusive. Recent publications have reported only 50% concordance between AVS and CT, with >10% of patients aged >50 lateralizing to opposite sides<sup>44,45</sup>. Therefore, in vivo measurement of adrenal *NPNT* could be a more accurate predictor of APA presence and even genotype, as the secreted protein may be measurable in adrenal vein samples routinely collected for unilateral APA diagnoses.

A limitation of the work to date is that the H295R cell-line is not a perfect model for native ZG cells or ZG-like APAs, even though H295R cells have proven invaluable in studying mechanisms involved in the physiological regulation of aldosterone production<sup>46</sup>. Therefore, in the adhesion studies, primary adrenal cell types were also utilized. In addition, the H295R cell-line is already known to harbour a *CTNNB1* mutation<sup>47</sup> with high levels of *NPNT*, so whenever applicable, silencing *NPNT* was prioritised. Furthermore, our work on malignant cells in this study has been carried out only on H295R, due to the lack of other human adrenal carcinoma cell-lines amenable to transfection. A further limitation is that centripetal migration of adrenocortical cells cannot be studied in human adrenal. Due to the dispersed-cell nature of the experiments which we can currently undertake, the effects of *NPNT*'s various roles in the adrenal may be under-estimated in this study. The full impact of *NPNT* will become apparent during experiments on intact adrenal with preserved cell-cell contacts. Future work may involve a ZG-selective conditional-knockout of *NPNT*, by crossing a floxed-*NPNT* mouse<sup>48</sup> with an aldosterone synthase-Cre recombinase mouse<sup>49</sup>.

In conclusion, we have discovered *NPNT* to be an exquisitely ZG-selective ECM protein in the adrenal. The distribution of *NPNT* defines the glomeruli anatomically, and its actions explain the critical role of glomerular structure in regulation of aldosterone production and

hence blood pressure control. The high levels of NPNT in the smaller aldosterone-dense ZG-like APA subtype, as well as in ACCs, suggest future potential as a diagnostic marker, or target for novel therapies.

## Perspectives

Primary aldosteronism is the most common secondary cause of hypertension, of which APAs make up 30-50% of cases, with hypertension potentially curable by adrenalectomy. Recently, the discovery of somatic mutations in *CACNA1D/ATP1A1/ATP2B3/CTNNB1* characterize a subtype of small ZG-like APAs that are also histologically and biochemically distinct from the classical large *KCNJ5*-mutant ZF-like APAs. Investigations into transcriptomic differences between the two subtypes revealed *NPNT*, encoding the matrix protein nephronectin, to be the most upregulated gene in ZG-like vs ZF-like APAs. Subsequent investigations have shown NPNT to be not just a biomarker of ZG-type APAs, but to play an important role in normal ZG. Found to be under canonical Wnt control, the distribution and effects of NPNT suggest that it defines the anatomy and function of normal adrenal glomeruli, driving steroidogenesis and adhesion physiologically. In contrast, in immortalized adrenocortical carcinoma cells, NPNT exerts anti-adhesive and anti-apoptotic effects. Clinical measurement of NPNT in adrenal vein blood may have application in diagnosis of unilateral APAs. Complete cure of hypertension, upon removal of *CTNNB1*-mutant APAs, may be predicted through unilateral detection of secreted proteins such as NPNT during adrenal vein sampling. Apart from its potential as a diagnostic marker, the high levels of *NPNT* in the smaller aldosterone-dense ZG-like APA subtype, and in ACCs, make it an attractive molecular target for novel therapies.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We thank the Cambridge NIHR BRC Cell Phenotyping Hub, in particular, Anna Petrunina Harrison and Simon McCallum and for their advice and support in flow cytometry.

### Sources of Funding

This research was funded by grants from the National Institute for Health Research (NIHR) Senior Investigator award (NF-SI-0512-10052) to M.J.B. A.E.D.T. is supported by the Agency for Science, Technology and Research (A\*STAR) Singapore, and the Wellcome Trust Translational Medicine and Therapeutics award to M.J.B. (085686/Z/08/A); S.G. is supported by the British Heart Foundation (FS/14/75/31134).; and J.Z. by the Cambridge Overseas Trust. Additional support was provided by the NIHR Cambridge Biomedical Research Centre (Cardiovascular and Metabolic, and Human Tissue Bank).

## References

1. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. *J Clin Endocrinol Metab.* 2004; 89:1045–1050. [PubMed: 15001583]

2. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *J Am Coll Cardiol.* 2006; 48:2293–2300. [PubMed: 17161262]
3. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. *Hypertension.* 2013; 62:331–336. [PubMed: 23753408]
4. Reincke M, Fischer E, Gerum S, et al. Observational study mortality in treated primary aldosteronism: The German conn's registry. *Hypertension.* 2012; 60:618–624. [PubMed: 22824982]
5. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2016; 101:1889–1916. [PubMed: 26934393]
6. Choi M, Scholl UI, Yue P, et al. K<sup>+</sup> channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science.* 2011; 331:768–772. [PubMed: 21311022]
7. Azizan EAB, Lam BYH, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ, Brown MJ. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa-and zona fasciculata-like tumors. *J Clin Endocrinol Metab.* 2012; 97:E819–829. [PubMed: 22442279]
8. Azizan EAB, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. *Nat Genet.* 2013; 45:1055–1060. [PubMed: 23913004]
9. Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. *Nat Genet.* 2013; 45:440–442. [PubMed: 23416519]
10. Teo AED, Garg S, Haris Shaikh L, Zhou J, Karet Frankl FE, Gurnell M, Happerfield L, Marker A, Bienz M, Azizan EAB, Brown MJ. Pregnancy, Primary Aldosteronism, and Adrenal CTNNB1 Mutations. *N Engl J Med.* 2015; 373:1429–1436. [PubMed: 26397949]
11. Nanba K, Tsuiki M, Sawai K, Mukai K, Nishimoto K, Usui T, Tagami T, Okuno H, Yamamoto T, Shimatsu A, Katabami T, et al. Histopathological diagnosis of primary aldosteronism using CYP11B2 immunohistochemistry. *J Clin Endocrinol Metab.* 2013; 98:1567–1574. [PubMed: 23443813]
12. Ono Y, Nakamura Y, Maekawa T, Felizola SJ, Morimoto R, Iwakura Y, Kudo M, Seiji K, Takase K, Arai Y, Gomez-Sanchez CE, et al. Different expression of 11 $\beta$ -hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas. *Hypertension.* 2014; 64:438–444. [PubMed: 24842915]
13. Chen YM, Wu KD, Hu-Tsai MI, Chu JS, Lai MK, Hsieh BS. Differential expression of type 1 angiotensin II receptor mRNA and aldosterone responsiveness to angiotensin in aldosterone-producing adenoma. *Mol Cell Endocrinol.* 1999; 152:47–55. [PubMed: 10432222]
14. Azizan EAB, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, Brown MJ, Shaughnessy KM. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. *Hypertension.* 2012; 59:587–591. [PubMed: 22252394]
15. Omura M, Sasano H, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism. *Hypertens Res.* 2006; 29:883–889. [PubMed: 17345788]
16. Brandenberger R, Schmidt A, Linton J, Wang D, Backus C, Denda S, Müller U, Reichardt LF. Identification and characterization of a novel extracellular matrix protein nephronectin that is associated with integrin  $\alpha$ 8 $\beta$ 1 in the embryonic kidney. *J Cell Biol.* 2001; 154:447–458. [PubMed: 11470831]
17. Fujiwara H, Ferreira M, Donati G, Marciano DK, Linton JM, Sato Y, Hartner A, Sekiguchi K, Reichardt LF, Watt FM. The basement membrane of hair follicle stem cells is a muscle cell niche. *Cell.* 2011; 144:577–589. [PubMed: 21335239]
18. Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC, Lavery GG, Parker KL, Hammer GD. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. *Development.* 2008; 135:2593–2602. [PubMed: 18599507]

19. Palacios G. Cell junctions in the adrenal cortex of the postnatal rat. *J Anat.* 1979; 129:695–701. [PubMed: 536307]
20. Hu C, Rusin CG, Tan Z, Guagliardo NA, Barrett PQ. Zona glomerulosa cells of the mouse adrenal cortex are intrinsic electrical oscillators. *J Clin Invest.* 2012; 122:2046–2053. [PubMed: 22546854]
21. Fallo F, Pezzi V, Barzon L, Mulatero P, Veglio F, Sonino N, Mathis JM. Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. *Eur J Endocrinol.* 2002; 147:795–802. [PubMed: 12457455]
22. Gomez-Sanchez CE, Qi X, Velarde-Miranda C, Plonczynski MW, Parker CR, Rainey W, Satoh F, Maekawa T, Nakamura Y, Sasano H, Gomez-Sanchez EP. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. *Mol Cell Endocrinol.* 2014; 383:111–117. [PubMed: 24325867]
23. Van Engeland M, Ramaekers FCS, Schutte B, Reutelingsperger CPM. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. *Cytometry.* 1996; 24:131–139. [PubMed: 8725662]
24. Aienza JM, Zhu J, Wang X, Xu X, Abassi Y. Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. *J Biomol Screen.* 2005; 10:795–805. [PubMed: 16234347]
25. Shaikh LH, Zhou J, Teo AED, Garg S, Neogi SG, Figg N, Yeo GS, Yu H, Maguire JJ, Zhao W, Bennett MR, et al. LGR5 activates noncanonical Wnt signaling and inhibits aldosterone production in the human adrenal. *J Clin Endocrinol Metab.* 2015; 100:E836–E844. [PubMed: 25915569]
26. Zhou J, Shaikh LH, Neogi SG, McFarlane I, Zhao W, Figg N, Brighton CA, Maniero C, Teo AED, Azizan EAB, Brown MJ. DACH1, a Zona Glomerulosa Selective Gene in the Human Adrenal, Activates Transforming Growth Factor-Signaling and Suppresses Aldosterone Secretion. *Hypertension.* 2015; 65:1103–1110. [PubMed: 25776071]
27. Sato Y, Uemura T, Morimitsu K, Sato-Nishiuchi R, Manabe R-I, Takagi J, Yamada M, Sekiguchi K. Molecular basis of the recognition of nephronectin by integrin alpha8beta1. *J Biol Chem.* 2009; 284:14524–14536. [PubMed: 19342381]
28. Kolligs F, Hu G, Dang C, Fearon E. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. *Mol Cell Biol.* 1999; 19:5696–5706. [PubMed: 10409758]
29. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. *Science (80- ).* 1997; 275:1784–1787.
30. Bieritz B, Spessotto P, Colombatti A, Jahn A, Prols F, Hartner A. Role of alpha8 integrin in mesangial cell adhesion, migration, and proliferation. *Kidney Int.* 2003; 64:119–127. [PubMed: 12787402]
31. Patra C, Ricciardi F, Engel FBF. The functional properties of nephronectin: an adhesion molecule for cardiac tissue engineering. *Biomaterials.* 2012; 33:4327–4335. [PubMed: 22436799]
32. Kelly P, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumorigenesis and cancer therapy. *Cell Death Differ.* 2011; 18:1414–1424. [PubMed: 21415859]
33. Åkerström T, Willenberg HS, Cupisti K, et al. Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas. *Endocr Relat Cancer.* 2015; 22:735–744. [PubMed: 26285814]
34. Warren HR, Evangelou E, Cabrera CP, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat Genet.* 2017; 49:403–415. [PubMed: 28135244]
35. Barrett PQ, Guagliardo NA, Klein PM, Hu C, Breault DT, Beenhakker MP. Role of voltage-gated calcium channels in the regulation of aldosterone production from zona glomerulosa cells of the adrenal cortex. *J Physiol.* 2016; 594:5851–5860. [PubMed: 26845064]
36. Okamura H, Doi M, Goto K, Kojima R. Clock genes and salt-sensitive hypertension: a new type of aldosterone-synthesizing enzyme controlled by the circadian clock and angiotensin II. *Hypertens Res.* 2016; 39:681–687. [PubMed: 27439492]
37. Inagaki FF, Tanaka M, Inagaki NF, Yagai T, Sato Y, Sekiguchi K, Oyaizu N, Kokudo N, Miyajima A. Nephronectin is upregulated in acute and chronic hepatitis and aggravates liver injury by

- recruiting CD4 positive cells. *Biochem Biophys Res Commun.* 2013; 430:751–756. [PubMed: 23206711]
38. Rao TP, Kühl M. An updated overview on wnt signaling pathways: A prelude for more. *Circ Res.* 2010; 106:1798–1806. [PubMed: 20576942]
39. Dzamba BJ, Jakab KR, Marsden M, Schwartz MA, DeSimone DW. Cadherin Adhesion, Tissue Tension, and Noncanonical Wnt Signaling Regulate Fibronectin Matrix Organization. *Dev Cell.* 2009; 16:421–432. [PubMed: 19289087]
40. Astudillo P, Larrain J. Wnt Signaling and Cell-Matrix Adhesion. *Curr Mol Med.* 2014; 14:209–220. [PubMed: 24467207]
41. Abraham S, Kogata N, Fässler R, Adams RH. Integrin  $\beta$ 1 subunit controls mural cell adhesion, spreading, and blood vessel wall stability. *Circ Res.* 2008; 102:562–570. [PubMed: 18202311]
42. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. *J Cell Biol.* 1994; 124:619–626. [PubMed: 8106557]
43. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. *J Pathol.* 2003; 200:500–503. [PubMed: 12845617]
44. Dekkers T, Prejbisz A, Kool LJS, et al. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: An outcome-based randomised diagnostic trial. *Lancet Diabetes Endocrinol.* 2016; 4:739–746. [PubMed: 27325147]
45. Zhu L, Zhang Y, Zhang H, Zhou W, Shen Z, Zheng F, Tang X, Tao B, Zhang J. Comparison between adrenal venous sampling and computed tomography in the diagnosis of primary aldosteronism and in the guidance of adrenalectomy. *Medicine (Baltimore).* 2016; 95:e4986. [PubMed: 27684853]
46. Bird IM, Hanley NA, Word RA, Mathis JM, McCarthy JL, Mason JI, Rainey WE. Human NCI-H295 adrenocortical carcinoma cells: A model for angiotensin-II-responsive aldosterone secretion. *Endocrinology.* 1993; 133:1555–1561. [PubMed: 8404594]
47. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré AM, René-Corail F, Jullian E, Gicquel C, Bertagna X, Vacher-Lavenu MC, et al. Mutations of  $\beta$ -catenin in adrenocortical tumors: Activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. *Cancer Res.* 2005; 65:7622–7627. [PubMed: 16140927]
48. Linton JM, Martin GR, Reichardt LF. The ECM protein nephronectin promotes kidney development via integrin  $\alpha$ 8 $\beta$ 1-mediated stimulation of Gdnf expression. *Development.* 2007; 134:2501–2509. [PubMed: 17537792]
49. Freedman B, Kempna P, Carlone D, Shah MS, Guagliardo N, Barrett P, Gomez-Sanchez C, Majzoub J, Breault DT. Adrenocortical zonation results from lineage conversion of differentiated zona glomerulosa cells. *Dev Cell.* 2013; 26:666–673. [PubMed: 24035414]

## Novelty and Significance

### What is new?


NPNT, selectively expressed in the zona glomerulosa of human adrenal cortex, and of APAs arising from this, is shown to have roles in steroidogenesis, cell-adhesion, and protection of adrenocortical cells from apoptosis.

### What is relevant?

APAs are greatly under-diagnosed, one reason being the small size of those appearing to arise in the ZG of adrenal cortex. Recognition of their separate identity, and of the role of NPNT in steroidogenesis, will encourage clinicians to give greater consideration to small adenomas.

### Summary

NPNT is an exquisitely selective, Wnt-driven ZG protein, which appears to play an important role in steroidogenesis, by promoting adhesion of ZG cells, and preventing apoptosis.




**Figure 1. NPNT is selectively expressed in normal adrenal ZG, ZG-like APAs and ACCs.**

(a). Microarray analysis of *NPNT*, comparing 8 ZF-like adenomas with 5 ZG-like adenomas  
 (b). qRT-PCR validation of *NPNT*, on mRNA extracted from 11 ZF-like APAs and 10 ZG-like APAs differentiated based on their genotypic mutations, as well as 6 ACCs.  
 (c). Microarray analysis of *NPNT*, comparing 20 paired ZF and ZG (each pair from the same patient), isolated via laser capture microdissection.  
 (d). Representative immunohistochemistry of NPNT showing selective extracellular localization in the ZG of adrenal adjacent to a pheochromocytoma (4x magnification) (inset: 20x magnification).


(e). Representative immunohistochemistry of NPNT comparing staining between ZF-like APA and ZG-like APA mounted on the same slide (4x magnification).

In **a-c**, bars represent mean expression per group  $\pm$  s.e.m. Statistical analyses were conducted by Student's *t*-test (**a,c**) or one-way ANOVA followed by Tukey's *post hoc* test (**b**). \* $P < 0.05$ ; \*\* $P < 0.005$ ; \*\*\* $P < 0.0005$ ; NS, not significant. M, medulla; ZG, zona glomerulosa; ZF, zona fasciculata.



**Figure 2. *NPNT* expression corresponds to *CYP11B2* expression, with presence of negative feedback**


- (a). Strong positive linear correlation between *NPNT* and *CYP11B2* expression in 10 pairs of adenomas and their adjacent adrenal,  $r(18)=0.8273$ ,  $p<0.0001$ . Inset: correlation plot excluding the 2 samples with highest *NPNT* expression,  $r(16)=0.6806$ ,  $p=0.0019$ . Statistical analysis was conducted by Pearson product-moment correlation.
- (b). Representative immunohistochemistry of *NPNT* and *CYP11B2* in corresponding ZG areas in serial sections of the same adrenal tissue (20x magnification).
- (c). Microarray expression of *NPNT* in 7 paired ZG and ZF samples adjacent to a phaeochromocytoma and 13 pairs next to an APA. Bars represent mean expression per group  $\pm$ s.e.m. Statistical analysis was conducted by one-way ANOVA followed by Tukey's *post hoc* test. \* $P<0.05$ ; \*\* $P<0.005$ ; \*\*\* $P<0.0005$ ; NS, not significant.
- (d). Negative feedback shown by representative immunohistochemistry of *NPNT*, in ZG adjacent to phaeochromocytoma compared to that adjacent to ZF-like or ZG-like APAs (20x magnification).



**Figure 3. NPNT drives aldosterone production, likely through receptor *ITGB1***

- (a). *NPNT* overexpression increases protein-normalized aldosterone production, compared to vector control (n=4).
- (b). *NPNT* silencing decreases protein-normalized aldosterone production, compared to non-targeting control (n=4).
- (c). *ITGB1* silencing decreases protein-normalized aldosterone production, compared to non-targeting control (n=4).

Bars represent mean expression per group  $\pm$  s.e.m. Statistical analyses were conducted by Student's *t*-test. \* $P < 0.05$ ; \*\* $P < 0.005$ ; \*\*\* $P < 0.0005$




**Figure 4. NPNT is a Wnt target gene and produces aldosterone via Wnt**

(a). Constitutive Wnt activation (  $\Delta$ N-Bcat) induces *NPNT* mRNA expression, while constitutive Wnt repression (  $\Delta$ N-TCF4) decreased *NPNT* expression compared to vector control (n=3).

(b). Wnt transcriptional complex TCF/LEF activity decreased in *NPNT*-overexpressed and increased in *NPNT*-silenced samples, as measured by firefly/renilla luciferase assay (n=6, n=4).

(c). Wnt inhibitor LGK-974 attenuated the increase in protein-normalized aldosterone production with addition of NPNT protein, compared to negative controls bovine serum albumin (BSA) and fibronectin (n=3).

Bars represent mean expression per group  $\pm$  s.e.m. Statistical analyses were conducted by Student's *t*-test. \* $P$ <0.05; \*\* $P$ <0.005; \*\*\* $P$ <0.0005




**Figure 5. NPNT is pro-adhesive in normal adrenal and APA cells, but anti-adhesive in H295R.**

(a). NPNT is pro-adhesive in i. HEK, ii. Normal primary adrenal, iii. ZF-like APA, iv. ZG-like APA, but anti-adhesive in v. H295R, as demonstrated by wells pre-coated with PBS, BSA, NPNT or laminin, and measured by Xcelligence cell impedance as cell index over time (4h for cell-lines, 10h for primary adrenal cells) (n=2 for ZF-like APA and ZG-like APA, n=4 for the rest).

(b). NPNT is anti-adhesive in H295R cells, as confirmed by Hoechst fluorescent stain assay measuring % maximum fluorescence as a representation of number of cells adhered to well with increasing concentrations of BSA, NPNT and laminin pre-coating (n=3 for each protein at each concentration).

Bars represent mean values per group  $\pm$  s.e.m.



**Figure 6. NPNT protects H295R cells from apoptosis**

(a). *NPNT* silencing causes cell confluency to remain low over 72h, as measured by kinetic live-cell imaging in groups that are untreated, treated with non-targeting siRNA or specific siRNA against *NPNT* (n=3, p<0.0001 between si*NPNT* and non-targeting).

(b). *NPNT* silencing drives active cell death, as shown by kinetic measurement of cytotoxicity using YOYO-1 iodide reagent, comparing number of fluorescent (dead) cells in groups that are untreated, treated with positive control puromycin, non-targeting siRNA or specific siRNA against *NPNT* (n=4, p<0.0001 between si*NPNT* and non-targeting)

(c). *NPNT* silencing causes cell death via apoptosis, as shown by flow cytometric analysis using annexin V-APC and PI double staining in groups that are treated with non-targeting siRNA or specific siRNA against *NPNT*. Quadrant analysis of the gated cells in FL-1 versus FL-2 channels was from 10,000 events. Annexin V+/PI- (lower right quadrant) areas stand for early apoptotic cells, and Annexin V+/PI+ (upper right quadrant) areas stand for late apoptotic or necrotic cells. Graph below shows percentage of total apoptotic cells at 12, 24, 36 and 48h post-silencing.

(d). *NPNT* silencing causes apoptosis through reduction of *BCL2*, a pro-survival factor in the intrinsic apoptotic pathway, as shown by mRNA expression in groups that are treated with non-targeting siRNA or specific siRNA against *NPNT* (n=6).

Bars represent mean expression per group  $\pm$  s.e.m. Statistical analyses were conducted by Student's *t*-test. \**P*<0.05; \*\**P*<0.005; \*\*\**P*<0.0005.